Back

Introduction: SGLT2 inhibitors beyond glycemic control.

30 June 2021 (16:50 - 16:53)
Organised by:
Congress Presentation Part of: SGLT2 inhibition in heart failure: what have we learned so far? Heart Failure Open Access Heart Failure 2021

About the speaker

Photo
Doctor Shelley Zieroth

St. Boniface Hospital, Winnipeg (Canada)

5 More presentations in this session

Presentation thumbnail
Impact of SGLT2 inhibitors on CV mortality, HF hospitalizations and clinical stability.
Professor M. Packer (Dallas, US)
Video
Presentation thumbnail
Renal benefits of SGLT2 inhibitors in HF patients.
Professor F. Zannad (Vandoeuvre-Les-Nancy, FR)
Video
Presentation thumbnail
Effects of SGLT2 inhibitors on quality of life in HF.
Professor J. Butler (Dallas, US)
Video
Presentation thumbnail
Safety of SGLT2 inhibitors with a focus on genital mycotic infections.
Professor G. Filippatos (Athens, GR)
Video
Presentation thumbnail
Conclusion.
Professor S. Anker (Berlin, DE)
Video

Access the full session

Session thumbnail
SGLT2 inhibition in heart failure: what have we learned so far?
Video

The Event

Event poster

Heart Failure 2021

30 June 2021 16:50 CET
You may be interested in
thumbnail
Congress Session
No time like the present: heart failure in the hospital setting
30 August 2024
thumbnail
Congress Presentation
Patient vascular model reveals anti-inflammatory effects of SGLT2 inhibitor by modulating endothelial-T cell crosstalk
31 August 2025
thumbnail
Congress Presentation
Cardiovascular benefits of SGLT2i in type 2 diabetes without heart failure: a subgroup analysis
30 August 2025
thumbnail
Congress Presentation
SGLT2 inhibitors for obesity
31 August 2024

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources